Retina

The OcuMet Beacon is a proprietary, noninvasive tool for assessing retinal health. The company said it will be available on the US market for use in clinics and health care institutions.

4D-150 is a potential backbone therapy that is designed to provide multiyear sustained delivery of anti-VEGF (aflibercept and anti–VEGF-C) to be targeted to the retina with a single, well-tolerated intravitreal injection.

Scientists enhance eye imaging with AI, achieving high-resolution views of retinal cells, potentially revolutionizing disease detection and monitoring in clinics.

A novel vitrectomy device shows promising safety and efficacy in the targeted removal of symptomatic vitreous opacities in pseudophakic eyes

Researchers evaluate key measures for tracking disease progression in Usher syndrome type 2–related retinal degeneration

Neurotech partners with Cencora for the U.S. launch of ENCELTO, the first FDA-approved treatment for MacTel, enhancing patient access and support.

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City, Utah.

Scientists enhance eye imaging with AI, achieving high-resolution views of retinal cells, potentially revolutionizing disease detection and monitoring in clinics.

Researchers unveil a groundbreaking method to stimulate retinal M cells, creating a new color, "olo," beyond human vision's natural limits.

A new event called SightLine and a series on adoption, implementation, integration (AII) draw the attention of ophthalmic administrators.

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

Authors defined metabolic syndrome as “the set of factors that increase the risk of cardiovascular disease and diabetes, such as hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia.”

Celebrating a half-century of progress with Ophthalmology Times.

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and broadening the dosing schedule to include every-4-week dosing across approved indications.

In their study, 16 ophthalmologists, including attending physicians and residents with levels of experience ranging from 1 to 9 years, were included.

VX01-DR-201, is a phase 2, multicenter, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME).

PYK-2101 is a focal hydrogel retinal sealant for use in patients undergoing surgery for a detached retina.

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts

Researchers introduce a multistage dual-branch network to improve accuracy and efficiency

In the European Union and United Kingdom, aflibercept 8 mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular edema

Below a specific threshold, FCP exerts a protective effect, but above that threshold the protective effect becomes uncertain.

The new data builds upon previously reported 6- and 12-month positive results from adult patients treated in the same study.

A study found that children with early-onset atopic dermatitis have a higher risk of developing uveitis and should be closely monitored for its onset.

In celebration of Ophthalmology Times' 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the past 5 decades.

Researchers from the Czech Republic found that an AI system showed higher sensitivity and specificity for screening diabetic retinopathy compared to telemedicine evaluations.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

Tertiary syphilis, which can develop years to decades after the initial infection, is characterized by chronic inflammatory damage affecting multiple organ systems.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.